Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.
The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Female with age greater than or equal to 18 years
Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion
Participant with no history of cancer
Male
Age less than 18 years old
Refusal to participate or withdrawal of consent
Pregnant and/or breastfeeding women
ScreenCell
Lead sponsor
AXELYS SANTE
Collaborator